Oxcarbazepine + CabotegravirContraindicated
Strong UGT1A1 inducer that significantly decreases cabotegravir plasma concentrations. Coadministration is contraindicated.
Source: NLP:cabotegravir
Oxcarbazepine Interactions
Brand names: Oxcarbazepine
Anti-epileptic Agent
Route: Oral
Contraindications
4 CONTRAINDICATIONS Oxcarbazepine tablets are contraindicated in patients with a known hypersensitivity to oxcarbazepine or to any of its components, or to eslicarbazepine acetate [ see Warnings and Precautions (5.2 , 5.3) ]. Known hypersensitivity to oxcarbazepine or to any of its components, or to eslicarbazepine acetate ( 4 , 5.2 )
Pregnancy & Breastfeeding
8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AEDs, such as oxcarbazepine tablets, during pregnancy. Encourage women who are taking oxcarbazepine tablets during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. Risk Summary There are no adequate data on the developmental risks associated with the use of oxcarbazepine tablets in pregnant women; however, oxcarbazepine tablets is closely related structurally to carbamazepine, which is considered to be teratogenic in humans. Data on a limited number of pregnancies from pregnancy registries suggest that oxcarbazepine tablets monotherapy use is associated with congenital malformations (e.g., craniofacial defects such as oral clefts, and cardiac malformations such as ventricular septal defects). Increased incidences of fetal structural abnormalities and other manifestations of developmental toxicity (embryolethality, growth retardation) were observed in the offspring of animals treated with either oxcarbazepine or its active 10-hydroxy metabolite (MHD) during pregnancy at doses similar to the maximum recommended human dose (MRHD). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Clinical Considerations An increase in seizure frequency may occur during pregnancy because of altered levels of the active metabolite of oxcarbazepine. Monitor patients carefully during pregnancy and through the postpartum period [see Warnings and Precautions (5.10) ] . Data Human Data Data from published registries have reported craniofacial defects such as oral clefts and cardiac malformations such as ventricular septal defects
28 interactions on record
Oxcarbazepine + DoravirineContraindicated
Co-administration decreases doravirine plasma concentrations. At least a 4-week cessation period is recommended prior to initiation of PIFELTRO.
Source: NLP:doravirine
Oxcarbazepine decreases lenacapavir concentration, risking loss of therapeutic effect and resistance. Concomitant use is not recommended.
Source: NLP:lenacapavir sodium
May reduce contraceptive effectiveness and result in unintended pregnancy or breakthrough bleeding by increasing metabolism of contraceptive steroids.
Source: NLP:norethindrone
Oxcarbazepine + CarbamazepineModerate
Carbamazepine decreases plasma levels of MHD (active metabolite) by 25-49%. Monitoring of MHD levels and oxcarbazepine dose adjustment may be necessary.
Source: NLP:oxcarbazepine
Induces CYP3A4 and may decrease plasma concentrations of desogestrel and ethinyl estradiol, potentially diminishing contraceptive effectiveness and increasing breakthrough bleeding.
Source: NLP:desogestrel and ethinyl estradiol
Induces CYP3A4 enzyme, may decrease effectiveness of COCs or increase breakthrough bleeding.
Source: NLP:drospirenone and ethinyl estradiol
Oxcarbazepine + Drospirenone, Ethinyl Estradiol And Levomefolate Calcium And Levomefolate CalciumModerate
May decrease the effectiveness of hormonal contraceptives or increase breakthrough bleeding through CYP3A4 enzyme induction.
Source: NLP:drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calcium
Oxcarbazepine + Drospirenone/Ethinyl Estradiol/Levomefolate Calcium And Levomefolate CalciumModerate
Enzyme inducer that may decrease effectiveness of COCs or increase breakthrough bleeding. Use back-up contraception.
Source: NLP:drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
Oxcarbazepine + EtonogestrelModerate
May decrease plasma concentrations of etonogestrel and diminish contraceptive effectiveness or increase breakthrough bleeding.
Source: NLP:etonogestrel
CYP3A4 enzyme inducer that may decrease plasma concentrations of etonogestrel and ethinyl estradiol, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.
Source: NLP:etonogestrel and ethinyl estradiol
May increase phenytoin serum levels; monitoring of phenytoin levels recommended.
Source: NLP:fosphenytoin sodium
Oxcarbazepine + HydrocortisoneModerate
CYP3A4 inducer may decrease serum hydrocortisone concentrations and increase risk of adrenal crisis; may require dose increase.
Source: NLP:hydrocortisone
Oxcarbazepine induces CYP3A4 and may decrease plasma concentrations of COCs, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.
Source: NLP:levonorgestrel and ethinyl estradiol and ferrous bisglycinate
Oxcarbazepine induces CYP3A4 enzymes, potentially decreasing contraceptive effectiveness and increasing breakthrough bleeding.
Source: NLP:norethindrone and ethinyl estradiol and ferrous fumarate
Enzyme inducer that may decrease plasma concentrations of contraceptive hormones and reduce effectiveness of hormonal contraceptives or increase breakthrough bleeding.
Source: NLP:levonorgestrel / ethinyl estradiol and ethinyl estradiol
May decrease effectiveness of medroxyprogesterone acetate through enzyme induction. Counsel use of back-up or alternative contraception.
Source: NLP:medroxyprogesterone acetate
Enzyme inducer that may decrease plasma concentrations of CHCs and potentially diminish effectiveness or increase breakthrough bleeding.
Source: NLP:norelgestromin and ethinyl estradiol
CYP3A4 inducer that may decrease the effectiveness of COCs or increase breakthrough bleeding.
Source: NLP:norethindrone acetate and ethinyl estradiol, and ferrous fumarate
Enzyme inducer that may decrease plasma concentrations of norethindrone and ethinyl estradiol, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.
Source: NLP:norethindrone and ethinyl estradiol
CYP3A4 enzyme inducer that may decrease plasma concentrations of COCs and potentially diminish contraceptive effectiveness or increase breakthrough bleeding.
Source: NLP:norgestimate and ethinyl estradiol
Oxcarbazepine may decrease the effectiveness of hormonal contraceptives, including oral and implant formulations.
Source: NLP:oxcarbazepine
Oxcarbazepine + PerampanelModerate
Decreases perampanel plasma concentrations by approximately 50-67%. Dose adjustment of FYCOMPA may be necessary; monitor closely when introduced or withdrawn.
Source: NLP:perampanel
Oxcarbazepine + PhenobarbitalModerate
Phenobarbital decreases plasma levels of MHD (active metabolite) by 25-49%. Monitoring of MHD levels and oxcarbazepine dose adjustment may be necessary.
Source: NLP:oxcarbazepine
Oxcarbazepine + PhenytoinModerate
Oxcarbazepine increases phenytoin levels at doses >1200 mg/day. Plasma level monitoring and dose reduction of phenytoin may be required.
Source: NLP:oxcarbazepine
Oxcarbazepine + Phenytoin SodiumModerate
May increase phenytoin serum levels; monitoring of phenytoin levels recommended.
Source: NLP:extended phenytoin sodium
Oxcarbazepine + RifampinModerate
Rifampin decreases plasma levels of MHD (active metabolite) by 25-49%. Monitoring of MHD levels and oxcarbazepine dose adjustment may be necessary.
Source: NLP:oxcarbazepine
Steady-state plasma concentrations of oxcarbazepine monohydroxy derivative were not affected by concomitant lacosamide at any dose in clinical studies.
Source: NLP:lacosamide